Cardiology – Page 7

Adipocyte-Cardiomyocyte Communication via Surface-Bound Adiponectin: Mechanisms of sEV Failure in Diabetic Ischemic Heart Failure

By MedXY 03/14/2026

This review explores how adipocyte-derived small extracellular vesicles (sEVs) use surface-bound adiponectin to protect the heart, and how diabetes-induced GRK2 upregulation disrupts this vital signaling pathway, leading to ischemic heart failure.

Cardiology news Otorhinolaryngology Pediatrics

A New Standard for Pediatric Vocal Fold Immobility After Cardiac Surgery: Improving Outcomes Through Injection Laryngoplasty

By MedXY 03/13/2026

Recent research highlights a standardized multidisciplinary protocol for managing unilateral vocal fold immobility in infants after cardiothoracic surgery, showing that injection laryngoplasty significantly improves oral feeding advancement and reduces dependence on feeding tubes.

Cardiology Hematology-Oncology news

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY 03/12/2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.

Cardiology news Oncology

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

By MedXY 03/12/2026

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and well-being, suggesting potential for individualized cardio-oncology interventions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

By MedXY 03/12/2026

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% relative risk reduction.

Cardiology Internal Medicine news

TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis

By MedXY 03/12/2026

New research identifies TRIM28 as a critical E3 ubiquitin ligase that degrades IRP2, thereby suppressing iron uptake and preventing myocardial ferroptosis during ischemia/reperfusion injury. This pathway, activated by p55γ and the drug perhexiline, offers a promising therapeutic target for patients with ischemic heart disease.

Cardiology Diabetes & Endocrinology news

Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations

By MedXY 03/11/2026

A large-scale target-trial emulation study reveals that tirzepatide significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to dulaglutide in patients with type 2 diabetes and ASCVD, while performing similarly to semaglutide.

Cardiology Clinical Updates news

Beyond Stenosis: The Prognostic Impact of Quantitative Plaque Volumetrics in Early Coronary Artery Disease

By MedXY 03/11/2026

This review synthesizes findings from a PROMISE trial substudy, revealing that quantitative coronary plaque volume and burden are independent predictors of MACE in symptomatic outpatients, even when total plaque levels are low.

Cardiology Internal Medicine news

Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment

By MedXY 03/11/2026

This article details the SCORE2-HF risk model, a newly validated tool designed to estimate 10-year and 30-year heart failure risks in asymptomatic individuals, enabling earlier intervention and personalized cardiovascular care across diverse European risk regions.

Cardiology news Pediatrics

Long-Term Reality of Single-Ventricle Reconstruction: Shunt Choice, Tricuspid Regurgitation, and the Burden of Global Morbidity

By MedXY 03/11/2026

A 16-year follow-up of the SVR trial reveals that while shunt types show similar long-term outcomes overall, pre-existing tricuspid regurgitation significantly impacts survival with RVPAS, amid a staggering 87% rate of major morbidity.

Cardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

By MedXY 03/11/2026

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.

Cardiology Emergency Medicine news

Novel Handheld Device More Than Doubles Success Rates of Valsalva Maneuver in Supraventricular Tachycardia: A Randomized Clinical Trial

By MedXY 03/11/2026

A randomized clinical trial published in JAMA Cardiology demonstrates that a handheld Valsalva assist device significantly improves sinus rhythm restoration in SVT patients, achieving a 63.2% success rate compared to just 29.2% with standard techniques.

Cardiology news Pediatrics

Beyond the Aorta: Genetic Stratification Redefines Mitral Valve Risk in Marfan Syndrome

By MedXY 03/11/2026

A breakthrough study reveals that specific FBN1 genotypes, particularly in-frame variants in the DNCD region, significantly elevate the risk of early mitral valve surgery in Marfan syndrome patients, paving the way for genotype-guided clinical surveillance.

Cardiology news Public Health

Severe Obesity Triples Heart Failure Risk: New Insights from the Cross-Cohort Collaboration

By MedXY 03/11/2026

A massive study of nearly 290,000 participants reveals that severe obesity (BMI ≥40) triples the risk of heart failure and nearly triples the risk of atrial fibrillation, with significant sex-based differences in stroke and mortality risk.

Cardiology news Pediatrics

Twice-Yearly Inclisiran Transforms LDL-C Management in Adolescents with HeFH: Insights from ORION-16

By MedXY 03/10/2026

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with heterozygous familial hypercholesterolaemia, offering a promising solution for long-term adherence and cardiovascular risk reduction in this high-risk pediatric population.

Cardiology Clinical Updates news

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

By MedXY 03/10/2026

This review synthesizes findings on how pregnancy biomarkers, particularly sFlt-1 and hs-cTnI, serve as early indicators of long-term maternal cardiovascular risk, offering a unique window for sex-specific prevention.

Cardiology news

Beyond the Culprit: Unmasking the Prevalence and Fate of Silent Plaque Ruptures in Non-Infarct-Related Arteries

By MedXY 03/10/2026

A landmark multimodality imaging study reveals that silent plaque ruptures occur in 12% of non-obstructive lesions in AMI patients. Over 50% of these ruptures heal within a year, highlighting the dynamic nature of coronary atherosclerosis and the importance of systemic secondary prevention strategies.

Cardiology news Pediatrics

Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation

By MedXY 03/10/2026

A large-scale analysis of 6,026 pediatric heart transplant candidates reveals that status exceptions often prioritize patients with lower mortality risk than those meeting standard criteria, highlighting a significant misalignment in the U.S. allocation system that the National Heart Review Board has yet to resolve.

Cardiology Clinical Updates news

Intramuscular Adipose Tissue Accumulation as a Key Determinant of Muscle Dysfunction in Peripheral Artery Disease

By MedXY 03/10/2026

This review synthesizes evidence that intramuscular adipose tissue (IMAT) accumulation, driven by fibroadipogenic progenitors, is a primary driver of limb dysfunction in PAD/CLTI, identifying IMAT as a novel therapeutic target.

Cardiology Critical Care news

Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock

By MedXY 03/10/2026

This clinical analysis of 500 patients identifies heart failure and arrhythmias as the primary causes of SCAI Stage B shock. Key findings highlight acute kidney injury and diuretic resistance as significant predictors of clinical deterioration and the need for escalation of care.